Update and controversies in prostate cancer

Session type:
Plenary Session 4
Info:
Tuesday, 15 April 2014, 08:00 to 13:50, eURO Auditorium
  1. Chair(s):P-A. Abrahamsson, Malmö (SE)

     A. Stenzl, Tuebingen (DE)

  2. State-of-the-art lecture: Genomic alterations and early-onset prostate cancer

    Duration:08:00 - 08:15

    Speaker:T. Schlomm, Hamburg (DE)

  3. Early Detection and Prevention of Prostate cancer Consensus Statement

    Duration:08:15 - 08:25

    Speaker:J. Cuzick, London (GB)

  4. Update: European Randomised Study of Screening for Prostate cancer (ERSPC)

    Duration:08:25 - 08:40

    Speaker:J.E. Hugosson, Göteborg (SE)

  5. Late breaking news: Efficacy and safety of DuodartTM treatment versus watchful waiting (WW) with step-up therapy to tamsulosin in the management of men with treatment-naïve, prostate enlargement, increased prostate-specific antigen (PSA) and moderately symptomatic benign prostatic hyperplasia (BPH): 2-Year CONDUCT study results

    Duration:08:40 - 08:50

    Speaker:C.G. Roehrborn, Dallas (US)

  6. Late breaking news: Active surveillance in HAROW – the first comprehensive prospective non-interventional study comparing treatment options in localized prostate cancer

    Duration:08:50 - 09:00

    Speaker:L. Weissbach, Fürth (DE)

  7. EAU Guidelines snapshot: PSA screening and risk stratification

    Duration:09:00 - 09:15

    Speaker:N. Mottet, Saint Etienne (FR)

  8. Case discussion: What's new in active surveillance

    Duration:09:15 - 09:55

    Moderator:N.W. Clarke, Manchester (GB)

    Panel:B. Malavaud, Toulouse (FR)

     P. Stattin, Umeå (SE)

     R.C.N. Van den Bergh, Utrecht (NL)

  9. State-of-the-art lecture: The association of BRCA mutations with prostate cancer risk and implications for management

    Duration:09:55 - 10:15

    Speaker:R.A. Eeles, London (GB)

  10. State-of-the-art lecture: Prediction of long-term adverse consequences of local treatment

    Duration:10:15 - 10:30

    Speaker:E.M. Johansson, Uppsala (SE)

  11. Late breaking news: Enzalutamide in men with chemotherapy-naïve metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study

    Duration:10:30 - 10:40

    Speaker:B. Tombal, Brussels (BE)

  12. State-of-the-art lecture: EUROCARE: Regional differences in Europe regarding survival of prostate cancer

    Duration:10:40 - 10:55

    Speaker:R. DeAngelis, Rome (IT)

  13. Case discussion: Early identification and management of oligometastatic disease

    Duration:10:55 - 11:35

    Moderator:C.P. Evans, Sacramento (US)

     Introduction

     C.P. Evans, Sacramento (US)

     How to reliably detect metastases

     C. La Fougère, Tübingen (DE)

     Possible systemic targets for treatment

     C.P. Evans, Sacramento (US)

     Radiate as much as you can

     D. Dearnaley, Sutton (GB)

     The case for metastasectomy

     S.G. Joniau, Leuven (BE)

     Case presentation and discussion

     C.P. Evans, Sacramento (US)

  14. Late breaking news: The International Consortium for Health Outcomes Measurement (ICHOM) activities on prostate cancer

    Duration:11:35 - 11:45

    Speaker:H. Huland, Hamburg (DE)

  15. Souvenir session by the EAU Scientific Congress Office

    Duration:11:45 - 13:45

     Benign prostate disease

     P. Radziszewski, Warsaw (PL)

     Prostate cancer: Screening, diagnostics and staging

     C.H. Bangma, Rotterdam (NL)

     Prostate cancer: Localised disease

     A. Briganti, Milan (IT)

     Prostate cancer: Systemic disease

     B. Tombal, Brussels (BE)

     Urothelial cancer of the urinary tract

     M. Roupret, Paris (FR)

     Renal cancer and transplantation

     A. Alcaraz, Barcelona (ES)

     Functional urology

     D.J.M.K. De Ridder, Leuven (BE)

     Endourology and technology

     A. De La Taille, Créteil (FR)

     Paediatric urology

     W.F.J. Feitz, Nijmegen (NL)

     Andrology

     J.O.R. Sonksen, Herlev (DK)

     Invasive and systemic urothelial cancer

     T.S. O'Brien, London (GB)

     Imaging in urology

     P. Albers, Düsseldorf (DE)

  16. Closing remarks

    Duration:13:45 - 13:50

    Speaker:P-A. Abrahamsson, Malmö (SE)

Aims and objectives

This session will include high profile presentations regarding “Controversies in Prostate Cancer”. These will include chemoprevention, genomic alterations of early onset prostate cancer, PSA screening and risk stratification, active surveillance, avoidance of local treatment morbidity, various aspects of oligometastatic disease and how to deal with possible predictive genetic changes without any clinical evidence of prostate cancer. Finally the souvenir sessions provide delegates with an overview of the 29th annual meeting with short highlights and future perspectives in the souvenir session. In this session members of the scientific committee of the EAU will give these overviews of various topics important to urologists.